Compare ARAY & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | NYXH |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.1M | 188.1M |
| IPO Year | 2007 | 2021 |
| Metric | ARAY | NYXH |
|---|---|---|
| Price | $0.99 | $4.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.50 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 1.2M | 56.3K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $450,902,000.00 | $6,616,215.00 |
| Revenue This Year | $3.82 | $79.25 |
| Revenue Next Year | $4.08 | $297.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.51 | ★ 10.96 |
| 52 Week Low | $0.91 | $4.35 |
| 52 Week High | $2.95 | $11.87 |
| Indicator | ARAY | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 48.96 |
| Support Level | $1.00 | $4.60 |
| Resistance Level | $1.06 | $5.01 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 34.85 | 83.33 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.